Cite
HARVARD Citation
Yanagisawa, T. et al. (2023). Docetaxel versus abiraterone for metastatic hormone‐sensitive prostate cancer with focus on efficacy of sequential therapy. Prostate. 83 (6), pp. 563-571. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Yanagisawa, T. et al. (2023). Docetaxel versus abiraterone for metastatic hormone‐sensitive prostate cancer with focus on efficacy of sequential therapy. Prostate. 83 (6), pp. 563-571. [Online].